M. Alexander Otto is a journalist who writes for Medscape, focusing on medical news and advancements in the field of oncology. With a particular interest in breast cancer research and treatment, Alexander covers topics such as new drug approvals, radiation therapy guidelines, and emerging technologies in cancer care.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
M. Alexander Otto specializes in healthcare and pharmaceutical topics, particularly focusing on the oncology field. His coverage heavily relies on data citations, indicating a preference for evidence-based information.
Given the technical nature of his articles and reliance on data citations, M. Alexander Otto would most likely respond well to pitches that provide scientific or medical experts who can offer in-depth insights into new treatments, clinical trial results, or emerging trends within the field of oncology and pharmaceuticals.
He does not appear to have a specific geographic focus but seems globally oriented when covering medical treatments and advancements in cancer care.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Immunotherapy has largely replaced chemotherapy as the last resort in patients at the end of life, but it's not always the right move.
Can patients with rectal cancer who have a near-complete clinical response to total neoadjuvant therapy be watched and potentially spared a permanent ostomy?
In a disease with dismal outcomes, KRAS inhibitors may offer hope for treating pancreatic cancer. But with preliminary data, experts remain cautiously optimistic.
After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or no PD-L1 expressors doesn't outweigh the risks.
Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes. But data on the practice remain limited.
Patients with this rare end-stage cancer complication achieved a median overall survival of nearly a year with proton craniospinal irradiation.
The oral small molecule is the first drug approved for a major driver of acute leukemia in infants.
Zanidatamab is the first agent approved specifically for advanced, HER2-positive second-line biliary tract cancer.
The CAIRO5 trial confirmed the benefit of both two-drug chemotherapy regimens with bevacizumab instead of a three-drug regimen.
At 2 years, results from the COMET trial suggest surveillance is safe, but longer follow-up is needed.
(833) 317-6278 
